Northwestern Mutual Wealth Management Co. Increases Stake in Boston Scientific Corporation $BSX

Key Points

• Northwestern Mutual Wealth Management Co. increased its holdings in Boston Scientific Corporation by 4.3%, owning a total of 749,398 shares valued at approximately $75.6 million.
• The company reported a quarterly earnings per share (EPS) of $0.75, exceeding analysts' expectations of $0.72, with a revenue of $5.06 billion, up 22.8% year-over-year.
• Multiple institutional investors, including GAMMA Investing LLC and Vanguard Group Inc., significantly raised their positions in Boston Scientific, highlighting strong institutional interest as they own 89.07% of the company's stock.

Northwestern Mutual Wealth Management Co. raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 749,398 shares of the medical equipment provider's stock after acquiring an additional 31,179 shares during the quarter. Northwestern Mutual Wealth Management Co. owned approximately 0.05% of Boston Scientific worth $75,599,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. NS Partners Ltd boosted its position in Boston Scientific by 1.6% during the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after acquiring an additional 5,704 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in Boston Scientific by 18.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after acquiring an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in Boston Scientific during the 1st quarter valued at $8,234,000. Finally, Blue Trust Inc. boosted its position in Boston Scientific by 13.0% during the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 575 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX stock traded down $0.45 during midday trading on Wednesday, reaching $105.94. The stock had a trading volume of 5,706,463 shares, compared to its average volume of 7,526,416. The stock has a market cap of $156.98 billion, a PE ratio of 63.06, a P/E/G ratio of 2.53 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a fifty day simple moving average of $104.27 and a two-hundred day simple moving average of $102.15. Boston Scientific Corporation has a 52-week low of $79.03 and a 52-week high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the business posted $0.62 EPS. The firm's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent research reports. Morgan Stanley increased their target price on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Truist Financial raised their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Robert W. Baird raised their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $117.50.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of Boston Scientific stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the transaction, the executive vice president owned 178,342 shares of the company's stock, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 345,029 shares of company stock worth $35,976,603 in the last ninety days. 0.50% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.